Goldman Sachs has initiated coverage on medical equipment maker ResMed and biotech giant CSL with a ‘buy’ ratings as analysts ...
In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...
The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
According to the latest Earnings Trends report, total S&P 500 earnings are expected to be up 7.4% from the year-ago period on ...
Zacks.com on MSN5d
5 Sectors and Stocks Set to Shine This Earnings SeasonThe fourth-quarter 2024 earnings season will kick off this week, with banking sector players due to report numbers. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback